Innovation has been the main criteria for Pharmaceutical companies, which has moved them away from internal R&D. More partnering deals are coming up with biotechs and academic centers. Also they are banking on low budget R&D to gain more on the licensing of essential compounds as well to seek out for profit gaining big-dollar deals. An increase in non-competitive venture groups is also expected with efforts to make drug development less risky and more of cost-effective.

Regulatory: According to the report, U.S. Food and Drug Administration have approved 30 new drugs in 2011 which is an increase from 21 of 2010. In 2012, a few more approvals will come up keeping the regulatory barriers intact for winning approval for new drugs. However, regulatory barriers in U.S is said to become more stringent which will make companies move to emerging markets for the first approval of their new products. It will be a tough time ahead for US Food and Drug Association (FDA) as companies will deviate their focus into markets outside United States.

Diagnostics: 2012 will see a lot of spending in the diagnostics sector of healthcare. Approval of new companion diagnostics will be on a rise. Companion diagnostics is that which assists physicians in making treatment decisions for their patients. Growth of predictive diagnostics and point-of-care diagnostics (fast and accurate point-of-care diagnostics that doctors can use anywhere) is also predicted. Predictive diagnostics helps to take preventive measures and also enhances individualized treatment approaches.

Sequencing: Sequencing as a technology deals with the genetics of diseases. The cost of genetic analysis is continuously dropping and we have already reached the $1,000 genome concept this year. This will continue to grow and develop a fast pace in genetically driven researches and development of more personalized medicines. Genetic technology is very important for doctors and patients to opt for more information for genetic diseases. Beijing Genomics Institute of China well known for Gene-Sequencing will be top listed as a leader in personalized medicine in the coming year.

Bioinformatics: A successful move in the history of medical science will be achieved only when we should be able to utilize the data which include Genome Graph data which will help manufacture more effective drugs at low cost with more impetus to prevention rather than cure. In 2012 more of such initiatives are on the fore front which includes major investments to carry out further researches on new challenges hitched out in the new era of genomics.

Emerging Markets: It would be an  eye watch  for 2012 to witness how the pharmaceutical cos cope up with the emerging markets as economic turmoil persist making an impact on the developed countries of the world. A challenge for Pharmaceutical cos on pricing is expected although growing middle class, the rising tide of chronic disease epidemic will keep the companies on the survival side, especially for branded generics. This will pave the way to more sources of revenue growth with added benefits. China will increase its productivity to enjoy the position of new innovation in the area of biotechnology.

Healthcare:  More of digital technology in the health care sector is making progress as dysfunctional U.S. healthcare system will be substituted by more of functional wellness-based system which will provide Predictive, Proactive, Pre-emptive approach in diagnostics.